Trial Profile
Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 13 Jun 2018 Status changed from recruiting to discontinued.
- 10 May 2016 According to CTI BioPharma media release, FDA has removed the clinical hold.
- 10 May 2016 Status changed from suspended to recruiting, as per CTI BioPharma media release.